Deborah Fein is Board of Trustees Distinguished Professor Emeritus in the Department of Psychological Sciences and the Department of Pediatrics at the University of Connecticut in Storrs.
Deborah Fein
Board of Trustees Distinguished Professor Emeritus
University of Connecticut
From this contributor
‘Prototypical autism’ research is likely a dead end
Efforts to define “frank” or “classic” forms of the condition build on several assumptions that the science has not yet borne out.
‘Prototypical autism’ research is likely a dead end
Journal club: Why do some children lose their autism diagnosis?
More than one-third of a cohort of autistic toddlers no longer meet criteria for the condition at school age, according to a new study, but the findings may not generalize because the cohort is predominantly white and affluent.
Journal club: Why do some children lose their autism diagnosis?
Screening toddlers for autism is worthwhile
A Norwegian study published in February suggested that the Modified Checklist for Autism in Toddlers fails to detect many cases of autism at 18 months of age. The creators of the test explain why there’s more to the story.
Screening toddlers for autism is worthwhile
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.